ResMed Inc. (RMD)

Market Cap	30.61B -13.2%
Revenue (ttm)	5.54B +10.3%
Net Income	1.52B +15.7%
EPS	10.37 +16.4%
Shares Out	145.06M
PE Ratio	20.04
Forward PE	17.38
Dividend	$2.40 (1.14%)
Ex-Dividend Date	May 14, 2026

Volume	351,064
Open	208.99
Previous Close	207.78
Day's Range	207.28 - 211.00
52-Week Range	198.61 - 293.81
Beta	0.84
Analysts	Buy
Price Target	270.60 (+28.22%)
Earnings Date	Apr 30, 2026

About RMD

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 2, 1995
• Employees: 9,980
• Stock Exchange: NYSE
• Ticker Symbol: RMD
• Website: https://www.resmed.com

Financial Performance

In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.

Analyst Summary

According to 19 analysts, the average rating for RMD stock is "Buy." The 12-month stock price target is $270.6, which is an increase of 28.22% from the latest price.

Price Target

$270.6

(28.22% upside)

Analyst Consensus: Buy